SG11201909924VA - Rapamycin analogs as mtor inhibitors - Google Patents
Rapamycin analogs as mtor inhibitorsInfo
- Publication number
- SG11201909924VA SG11201909924VA SG11201909924VA SG11201909924VA SG 11201909924V A SG11201909924V A SG 11201909924VA SG 11201909924V A SG11201909924V A SG 11201909924VA SG 11201909924V A SG11201909924V A SG 11201909924VA
- Authority
- SG
- Singapore
- Prior art keywords
- redwood city
- revolution
- medicines
- saginaw
- drive
- Prior art date
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 3
- 229940124302 mTOR inhibitor Drugs 0.000 title abstract 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title abstract 2
- 240000005020 Acaciella glauca Species 0.000 abstract 13
- 239000003814 drug Substances 0.000 abstract 13
- 235000003499 redwood Nutrition 0.000 abstract 13
- 229940079593 drug Drugs 0.000 abstract 9
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940102098 revolution Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT ill 1111u°11111OlDIIl ono o Mo IIH mIIII111110uDIIIIII (10) International Publication Number WO 2018/204416 Al (51) International Patent Classification: C07D 498/18 (2006.01) A61P 25/00 (2006.01) A61K 31/436 (2006.01) A61P 35/00 (2006.01) A61K 31/519 (2006.01) A61P 37/00 (2006.01) CO7D 519/00 (2006.01) (21) International Application Number: PCT/US2018/030531 (22) International Filing Date: 01 May 2018 (01.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/500,410 02 May 2017 (02.05.2017) US (71) Applicant: REVOLUTION MEDICINES, INC. [US/US]; 700 Saginaw Drive, Redwood City, CA 94063 (US). (72) Inventors; and (71) Applicants: SEMKO, Christopher [US/US]; c/o Revolu- tion Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). PITZEN, Jennifer [DE/US]; c/o Revolu- tion Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). WANG, Gang [CN/US]; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). TIBREWAL, Nidhi [IN/US]; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). (72) Inventors: AGGEN, James Bradley; c/o Revolution Med- icines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). THOTTUMKARA, Arun P.; c/o Revolution Medi- cines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). BURNETT, G. Leslie; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). GLIEDT, Micah James Evans; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). KISS, Gert; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). WON, Walter; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). LEE, Julie Chu-li; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). GILL, Adrian Liam; c/o Revolution Medi- cines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). (74) Agent: TONG, Connie C. et al.; Cooley LLP, 1299 Penn- sylvania Avenue, NW, Suite 700, Washington, DC 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: RAPAMYCIN ANALOGS AS MTOR INHIBITORS (57) : The present disclosure relates to rapamycin analogs of the general Formula (I). The compounds are inhibitors of mTOR and Me OMe Me Me thus useful for the treatment of cancer, immune-mediated diseases and R 3M Rao age related conditions. e [Continued on next page] W O 20 18/ 20 4416 Al WO 2018/204416 Al O II Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500410P | 2017-05-02 | 2017-05-02 | |
| PCT/US2018/030531 WO2018204416A1 (en) | 2017-05-02 | 2018-05-01 | Rapamycin analogs as mtor inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909924VA true SG11201909924VA (en) | 2019-11-28 |
Family
ID=62563244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909924V SG11201909924VA (en) | 2017-05-02 | 2018-05-01 | Rapamycin analogs as mtor inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210094975A1 (en) |
| EP (1) | EP3619216A1 (en) |
| JP (2) | JP7348071B2 (en) |
| KR (1) | KR20200012876A (en) |
| CN (1) | CN110770243A (en) |
| AU (2) | AU2018263886C1 (en) |
| CA (1) | CA3061907A1 (en) |
| IL (2) | IL270333B2 (en) |
| MX (2) | MX2019013031A (en) |
| SG (1) | SG11201909924VA (en) |
| WO (1) | WO2018204416A1 (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107073066B (en) | 2014-09-11 | 2021-09-17 | 加利福尼亚大学董事会 | mTORC1 inhibitors |
| UY37900A (en) | 2017-09-26 | 2019-04-30 | Novartis Ag | NEW DERIVATIVES OF RAPAMYCIN |
| IL312291A (en) | 2018-05-01 | 2024-06-01 | Revolution Medicines Inc | C26-linked rapamycin analogs as mtor inhibitors |
| BR112020022201A2 (en) * | 2018-05-01 | 2021-02-02 | Revolution Medicines, Inc. | analogues of rapamycin bound to c40, c28, and c-32 as inhibitors of mtor |
| IL279329B2 (en) * | 2018-06-15 | 2025-01-01 | Navitor Pharm Inc | Rapamycin analogs and uses thereof |
| LT3898637T (en) * | 2018-12-18 | 2025-03-10 | Novartis Ag | Rapamycin derivatives |
| MX2021010319A (en) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof. |
| KR20210146288A (en) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | Bicyclic heterocyclyl compounds and uses thereof |
| KR102497821B1 (en) * | 2019-08-23 | 2023-02-08 | 이화여자대학교 산학협력단 | Novel mTOR inhibitor compounds and the use thereof |
| EP4054720A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
| US11608346B2 (en) | 2019-11-04 | 2023-03-21 | Revolution Medicines, Inc. | Ras inhibitors |
| US11566007B2 (en) | 2019-11-04 | 2023-01-31 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4620531A3 (en) | 2019-11-08 | 2025-11-26 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| JP2023505100A (en) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | Covalent RAS inhibitors and uses thereof |
| JP2023506410A (en) | 2019-12-05 | 2023-02-16 | アナクリア セラピューティクス， インコーポレイテッド | Rapamycin analogues and uses thereof |
| WO2021142026A1 (en) | 2020-01-07 | 2021-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
| WO2021167175A1 (en) * | 2020-02-21 | 2021-08-26 | 한국과학기술원 | Pharmaceutical composition for preventing or treating cancer, comprising mtor-signaling inhibitor as active ingredient |
| TW202214253A (en) | 2020-06-18 | 2022-04-16 | 美商銳新醫藥公司 | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| WO2022020522A2 (en) * | 2020-07-21 | 2022-01-27 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| CR20230165A (en) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Indole derivatives as ras inhibitors in the treatment of cancer |
| AR124449A1 (en) | 2020-12-22 | 2023-03-29 | Qilu Regor Therapeutics Inc | SOS1 INHIBITORS AND USES THEREOF |
| IL307600A (en) * | 2021-04-09 | 2023-12-01 | Revolution Medicines Inc | Synthesis of rapamycin analog compounds |
| CN118561952A (en) | 2021-05-05 | 2024-08-30 | 锐新医药公司 | RAS inhibitors |
| CR20230558A (en) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | RAS INHIBITORS FOR CANCER TREATMENT |
| CN117500811A (en) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | Covalent RAS inhibitors and their uses |
| EP4359417A2 (en) * | 2021-06-25 | 2024-05-01 | Apertor Pharmaceuticals, Inc. | Small molecule compounds |
| CN114044775B (en) * | 2021-08-30 | 2023-04-07 | 杭州医学院 | Compound for target ubiquitination induction of BCR-ABL protein degradation and application thereof |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| EP4448526A1 (en) | 2021-12-17 | 2024-10-23 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| JP2025510572A (en) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | Methods for treating immunorefractory lung cancer |
| CN119604293A (en) | 2022-05-25 | 2025-03-11 | 锐新医药公司 | Methods of treating cancer with mTOR inhibitors |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AR132338A1 (en) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | RAS INHIBITORS |
| KR20250172857A (en) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Crystalline form of RAS inhibitor |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (en) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ras inhibitors |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04230389A (en) * | 1990-07-16 | 1992-08-19 | American Home Prod Corp | Rapamycin derivative |
| US5221740A (en) | 1992-01-16 | 1993-06-22 | American Home Products Corporation | Oxepane isomers of rapamycin useful as immunosuppressive agents |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US5741677A (en) | 1995-06-07 | 1998-04-21 | Geron Corporation | Methods for measuring telomere length |
| ES2219388T3 (en) * | 1999-08-24 | 2004-12-01 | Ariad Gene Therapeutics, Inc. | 28-EPI-RAPALOGOS. |
| EP1856131A1 (en) | 2005-03-07 | 2007-11-21 | Wyeth | Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin |
| CA2630271C (en) | 2005-11-17 | 2014-04-08 | Osi Pharmaceuticals, Inc. | Fused bicyclic mtor inhibitors |
| BRPI0715888B1 (en) | 2006-08-23 | 2021-11-03 | Kudos Pharmaceuticals Limited | COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND |
| EP1916006A1 (en) | 2006-10-19 | 2008-04-30 | Albert Schömig | Implant coated with a wax or a resin |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| US20110098241A1 (en) * | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
| US8394818B2 (en) | 2008-10-17 | 2013-03-12 | Dana-Farber Cancer Institute, Inc. | Soluble mTOR complexes and modulators thereof |
| NZ596552A (en) | 2009-05-26 | 2014-02-28 | Exelixis Inc | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| HK1198579A1 (en) | 2011-08-10 | 2015-04-30 | Novartis Pharma Ag | Jak p13k/mtor combination therapy |
| AU2012395673A1 (en) * | 2012-11-30 | 2014-08-14 | Hangzhou Zylox Pharma Co., Ltd. | Rapamycin analogs and methods for making same |
| US11116847B2 (en) | 2013-12-19 | 2021-09-14 | Seagen Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
| CN105461738B (en) * | 2014-06-03 | 2019-03-08 | 中国人民解放军军事医学科学院毒物药物研究所 | A kind of rapamycin derivative, its preparation method, its pharmaceutical composition and use |
| KR101668590B1 (en) * | 2014-06-19 | 2016-10-25 | 전남대학교병원 | Bioactive Peptide-coated Stent Promotes Endothelial Cell Proliferation and Prevents Stent Thrombosis |
| CN107073066B (en) * | 2014-09-11 | 2021-09-17 | 加利福尼亚大学董事会 | mTORC1 inhibitors |
| ES2881305T3 (en) * | 2014-12-17 | 2021-11-29 | Siemens Healthcare Diagnostics Inc | Sandwich Assay Design for Small Molecules |
| WO2017044720A1 (en) * | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
-
2018
- 2018-05-01 SG SG11201909924V patent/SG11201909924VA/en unknown
- 2018-05-01 JP JP2019560354A patent/JP7348071B2/en active Active
- 2018-05-01 EP EP18730160.1A patent/EP3619216A1/en active Pending
- 2018-05-01 IL IL270333A patent/IL270333B2/en unknown
- 2018-05-01 IL IL303660A patent/IL303660A/en unknown
- 2018-05-01 CA CA3061907A patent/CA3061907A1/en active Pending
- 2018-05-01 MX MX2019013031A patent/MX2019013031A/en unknown
- 2018-05-01 WO PCT/US2018/030531 patent/WO2018204416A1/en not_active Ceased
- 2018-05-01 CN CN201880038307.7A patent/CN110770243A/en active Pending
- 2018-05-01 KR KR1020197035460A patent/KR20200012876A/en not_active Ceased
- 2018-05-01 AU AU2018263886A patent/AU2018263886C1/en active Active
-
2019
- 2019-10-30 US US16/669,319 patent/US20210094975A1/en not_active Abandoned
- 2019-10-31 MX MX2023000410A patent/MX2023000410A/en unknown
-
2022
- 2022-03-11 US US17/693,225 patent/US20230093861A1/en not_active Abandoned
- 2022-11-10 AU AU2022268372A patent/AU2022268372A1/en not_active Abandoned
-
2023
- 2023-05-17 JP JP2023081189A patent/JP2023103387A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018204416A1 (en) | 2018-11-08 |
| IL270333B1 (en) | 2023-07-01 |
| RU2019138161A (en) | 2021-06-02 |
| JP7348071B2 (en) | 2023-09-20 |
| CN110770243A (en) | 2020-02-07 |
| IL303660A (en) | 2023-08-01 |
| JP2020518632A (en) | 2020-06-25 |
| US20210094975A1 (en) | 2021-04-01 |
| IL270333A (en) | 2019-12-31 |
| EP3619216A1 (en) | 2020-03-11 |
| JP2023103387A (en) | 2023-07-26 |
| AU2018263886B2 (en) | 2022-08-11 |
| CA3061907A1 (en) | 2018-11-08 |
| US20230093861A1 (en) | 2023-03-30 |
| RU2019138161A3 (en) | 2021-08-13 |
| AU2018263886C1 (en) | 2022-12-22 |
| IL270333B2 (en) | 2023-11-01 |
| MX2019013031A (en) | 2020-08-03 |
| MX2023000410A (en) | 2023-02-02 |
| KR20200012876A (en) | 2020-02-05 |
| AU2018263886A1 (en) | 2019-11-28 |
| AU2022268372A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909924VA (en) | Rapamycin analogs as mtor inhibitors | |
| SG11201906209SA (en) | Bicyclic compounds as allosteric shp2 inhibitors | |
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201908619TA (en) | Pd-1/pd-l1 inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201407537YA (en) | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201804890TA (en) | Bipyrazolyl derivatives useful for the treatment of autoimmune diseases | |
| SG11201407919WA (en) | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
| SG11201909429VA (en) | 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201408123SA (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations |